Pfizer’s Kelly alludes to universal healthcare

Share this article:
Pfizer's president of U.S. pharmaceuticals Pat Kelly said in a recent interview that the  "combination of the largest elements of our health system working together," is where the most progress toward helping America's uninsured is being made.
Kelly issued the remarks in an interview with the North Carolina newspaper, The Winston-Salem Journal.
When asked about the solution to the problem of America's uninsured, Kelly responded:
"If you did the combination of . . . an extension of a national, federal-based health program to create some base level of coverage – and I mean a very base level of coverage for everybody – then you add to that incentives for employers to continue coverage for either retirees or their actives, and then special incentives for small employers. That is where the issue is. The vast majority of the uninsured who are employed are employed in small business – the vast majority."
Kelly was in North Carolina last month to bring a program providing free drugs to the uninsured, called Sharing the Care, to a community health center there.
Kelly is the son of the newspaper's late executive editor and worked for the publication as a reporter one summer while attending Duke University.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...